摘要
多发性骨髓瘤(MM)是一种单克隆浆细胞异常增生所致的恶性肿瘤,被认为是一种不能治愈的疾病,传统治疗以化疗为主,但是疗效欠佳。蛋白酶体抑制剂硼替佐米作为一种全新的靶向治疗药物,通过阻滞核因子κB(NF-κB)的活性、增强肿瘤细胞对皮质激素和传统细胞毒性药物的敏感性,可在多种恶性肿瘤细胞中诱导细胞凋亡,临床上用于治疗复发性、难治性或初治的MM,有硼替佐米参与的联合化疗大大提高了患者的缓解率。
Multiple myeloma（MM） is a malignancy due to abnormal proliferation of monoclonal plasma cell, which is considered to be an incurable disease. The traditional treatment is chemotherapy ,but the effeet is poor. As a new targeted therapy drug,the proteasome inhibitor bortezomib induces apoptosis in a variety of malignant cells by blocking the activity of the nuclear transcription factor-KB （NF-B） and enhancing the sen- sitivity to cortieosteroids and traditional cytotoxie drugs. Bortezomlb therapy has be：ome an important part of the standard combined chemotherapy for patients with lapsed, refractory and initially treated muhiple myeloma. It has significantly improved remission rates of patients.
出处
《医学综述》
2013年第19期3504-3506,共3页
Medical Recapitulate
基金
国家自然科学基金(31260232)
云南省中青年学术技术带头人后备人才培养项目(2010CI013)
云南省科技厅-昆明医科大学应用基础研究联合专项基金(2012FB031)
